Atezolizumab for Idiopathic Pulmonary Fibrosis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT05515627
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks

Study Details

The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).

Key Dates

Start date
Feb 15, 2023
Status verified
Feb 2026
Primary completion
Jun 30, 2026
Completion
Apr 30, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab
    Atezolizumab 1200 mg IV every 3 weeks for 24 weeks

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048-

Find similar trials in Los Angeles, CA

By research site
Cedars-Sinai Medical Center· Los Angeles, CA

Related Studies